Biotech's Golden Moment

Biotechs are not as broadly and deeply affected by COVID-19 disruption and now lead the market as the economy begins the recovery process.Healthcare has attracted growing investor interest due to

PrudentBiotech.com ~ Covid-19 Virus

Biotech Melt-up

A high daily death toll suggests a much more careful and measured reopening of the economy will be possible, not a quick-paced one.The pandemic thrusts the biotechnology and the pharmaceutical

Continue Reading

PrudentBiotech.com ~ Healthcare and Bear Market

Healthcare In A Bear Market

Stocks plunge into a bear market as the viral outbreak threatens to devastate the economy.Healthcare has performed relatively better than the broader market which already has plunged over 30%.The healthcare

Continue Reading

Medicare for All

Biotechs Feel The Bern

 Healthcare is entering a period where election cycle impact will grow. The Medicare for All healthcare plan will begin to get factored based on the success of the proponents in the

Continue Reading

llustration - The New York Times, Nicholas Konrad; Photograph Anna Moneymaker

Healthcare On The March

Last week, the enormity of the risk for healthcare diminished and investors reacted favorably.Healthcare lags the broader market quite significantly, and specifically, biotechs and pharmaceuticals lag even more so.We continue

Continue Reading

Biotech Stocks - Cells

Biotechs Second Half Battle

Biotech indexes have remained subdued as the broader market has rallied.The broader healthcare sector and biopharma industries, in particular, remain under regulatory duress just as they have been for some

Continue Reading

PrudentBiotech.com ~ Gene Therapy

3 Gene Therapy Stocks

Biotech stocks and the broader healthcare sector remain under pressure.Promising opportunities exist in the small-cap and mid-cap segments.Gene therapy remains the emerging scientific frontier in biotech.3 promising small-cap gene therapy

Continue Reading

PrudentBiotech.com ~ Alzheimer

Biotech M&A Theme Builds Momentum

Biotech transaction activity continues to be sustained and well ahead of last year. Recent industry survey indicates a strong expectation by industry insiders of future biotech M&A transactions. A

Continue Reading

Biotech Bonanza: 2019 Outlook

2018 was a harder year than envisioned, even though second-half turbulence was somewhat anticipated The biotechnology sector provided opportunities for attractive returns during 2018 although the late-year decline rapidly

Continue Reading

PrudentBiotech.com ~ DNA Strand - Biotech Stocks

A Migrating Biotech Bear

Biotech sector achieves the dubious distinction of being amongst the first to slip over the Bear market threshold. Nonetheless, this should be a transitory bear market for biotechs, as

Continue Reading

PrudentBiotech.com ~ Biotech Stocks

The Biotech Conundrum!

Biotech stocks are performing well with double-digit gains for key indexes so far in 2018. Nonetheless, the biotech stock index returns do not appear to be favorable to the

Continue Reading

PrudentBiotech.com ~ Biotech Stocks

Biotech: The Gates Begin To Open

Biotech sector starts off the year strong with multiple acquisitions and partnerships, beginning to usher in the long-awaited M&A boom. Furthermore, unlike last October, earnings season this time

Continue Reading

PrudentBiotech.com - Biotech Stocks - Graycell Advisors - Stock Newsletters

Biotech: Opportunity Ahead!

November 30, 2017 Biotechnology sector has corrected over 10%. Poor earnings of larger biotechs knocked the wind out of the sector. An imminent catalyst can push the sector higher, recovering

Continue Reading

PrudentBiotech.com - Biotech Stocks - Graycell Advisors - Stock Newsletters

Biotech’s Best Chance!

June 8, 2017 A possible "Comey Rally" Favorable market environment for Biotechs Positive news flow from ASCO Potential catalysts - M&A, broader market advance, and health care policy clarity   Biotechnology

Continue Reading

Graycell Advisors ~ Prudent Biotech

Biotechnology: Ready for New Highs!

February 09, 2017 Biotechs and pharmas remain under the cloud of uncertain policy But recent developments increase confidence on the regulatory front Sufficient biotech sector drivers now exist to create

Continue Reading

Biotechnology Stocks - Prudent Biotech

Biotechnology: Is 2017 A Bonanza Year?

January 11, 2017 Biotechnology sector was one of the worst performing sectors in 2016. Political uncertainty has diminished but is still impairing investor confidence Signs are present for the sector to

Continue Reading

The Thundering Quant Bulls

APRIL 21, 2016 Yesterday, April 20, the S&P500 reached a critical stock market technical level of 2100. This is the level around which the index had peaked in November 2015. Why is this

Continue Reading

Stock Market Decline

Don’t Go Chasing The Market Lows!

JANUARY 15, 2016 Don’t Go Chasing Market Lows … they just keep getting lower! Biotechs represent a sector with tremendous potential. At the same time, it’s a highly volatile sector and quite

Continue Reading

Biotech Stocks - DNA Helix

Biotech Stocks Can’t Be Ignored!

DECEMBER 2015 Biotech is a sector that has outperformed the market meaningfully over a market cycle The general perception of the sector being highly risky overlooks a portfolio approach as well as

Continue Reading